NewLink Genetics Corporation (NLNK)
(Delayed Data from NSDQ)
$1.79 USD
+0.06 (3.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.78 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.79 USD
+0.06 (3.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.78 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
NewLink (NLNK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to updates on NewLink's (NLNK) merger with Lumos Pharma, when the former releases fourth-quarter 2019 results.
Company News For Dec 26, 2019
by Zacks Equity Research
Companies In The News Are: SSNT, NLNK, CVM, AXE
Do Options Traders Know Something About NewLink Genetics (NLNK) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
Company News For Sep 19, 2019
by Zacks Equity Research
Companies in the news are: FDX, BYND, SPI, NLNK
Is the Options Market Predicting a Spike in NewLink Genetics (NLNK) Stock?
by Zacks Equity Research
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
Implied Volatility Surging for NewLink Genetics (NLNK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
Celgene (CELG) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
4 Small Biotech Stocks Likely to Witness More Upside in 2019
by Zacks Equity Research
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
Is the Options Market Predicting a Spike in NewLink Genetics (NLNK) Stock? (revised)
by Zacks Equity Research
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Hertz NewLink Genetics (NLNK) Stock?
by Zacks Equity Research
Investors need to pay close attention to Hertz NewLink Genetics (NLNK) stock based on the movements in the options market lately.
NewLink Genetics (NLNK) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
NewLink (NLNK) delivered earnings and revenue surprises of 52.38% and -94.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
NewLink Genetics (NLNK) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
NewLink (NLNK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NewLink Shares Plunge After Incyte & Merck's Study Fails
by Zacks Equity Research
Shares of NewLink Genetics Corp. (NLNT) plunged about 42.6% following the news of the failure of Incyte and Merck's phase III combination study for metastatic melanoma.
Incyte's Epacadostat Fails in Melanoma Study, Shares Plunge
by Zacks Equity Research
Incyte's (INCY) epacadostat in combination with Merck's Keytruda fails to meet primary endpoint of PFS in a phase III melanoma study.
Options Traders Expect Huge Moves in NewLink Genetics (NLNK) Stock
by Zacks Equity Research
Surging implied volatility makes NewLink Genetics (NLNK) stock lucrative to the option traders.
NewLink Genetics (NLNK) Jumps: Stock Rises 29.9%
by Zacks Equity Research
NewLink Genetics (NLNK) shares rose nearly 30% in the last trading session, amid huge volumes.
Options Traders Expect Huge Moves in NewLink Genetics (NLNK) Stock
by Zacks Equity Research
High level of implied volatility makes NewLink Genetics (NLNK) Stock lucrative to the option traders.
Are Options Traders Betting on a Big Move in NewLink (NLNK) Stock?
by Zacks Equity Research
NewLink (NLNK) needs Investors to pay close attention to the stock based on moves in the options market lately.
NewLink Genetics (NLNK): Moving Average Crossover Alert
by Zacks Equity Research
NewLink Genetics Corporation (NLNK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Will NewLink Genetics (NLNK) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in NewLink Genetics Corp (NLNK).
NewLink Genetics (NLNK) Jumps: Stock Adds 10% in Session
by Zacks Equity Research
NewLink Genetics Corporation (NLNK) shares rose almost 10% in the last trading session.